公开(公告)号：US20050233941A1

公开(公告)日：2005-10-20

申请号：US10507254

申请日：2003-05-07

申请人： Jose Carballido Herrera ,  Jan Vries ,  Juliana Kund

发明人： Jose Carballido Herrera ,  Jan Vries ,  Juliana Kund

IPC分类号： G01N33/53 ,  A61K38/00 ,  A61K45/00 ,  A61P37/06 ,  A61P37/08 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  G01N33/543 ,  G01N33/566 ,  A61K38/17 ,  C07K14/715 ,  G01N33/567

CPC分类号： G01N33/505 ,  G01N33/5008 ,  G01N33/5023

摘要： A method for identifying an agent that has an influence on the amount of an analyte expressed by a cell, said method comprising stimulating a cell to produce at least 2 analytes, forming, in the absence and in the presence of a candidate compound, on the pins of a matrix at least 2 recognition complexes between an analyte and a recognition molecule, treating said recognition complexes with detection molecules to obtain on the pins of the matrix detection complexes, determining each amount of each detection complex formed on the pins, comparing each amount of detection complex formed in the absence and in the presence of a candidate compound, and choosing a candidate compound which has an influence on the amount of at least one of the detection complexes formed as a pharmaceutical agent.

摘要翻译： 一种用于鉴定对由细胞表达的分析物的量具有影响的试剂的方法，所述方法包括刺激细胞以产生至少2种分析物，在候选化合物不存在和存在的情况下，在 基质的针脚在分析物和识别分子之间至少2个识别复合物，用检测分子处理所述识别复合物以获得在基质检测复合物的引脚上，确定在引脚上形成的每个检测复合物的每个量，比较每个量 在不存在和存在候选化合物的情况下形成的检测复合物，并且选择对形成为药剂的至少一种检测复合物的量具有影响的候选化合物。

公开(公告)号：US20060088525A1

公开(公告)日：2006-04-27

申请号：US11297317

申请日：2005-12-08

申请人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

发明人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

IPC分类号： A61K39/395 ,  C07K16/44

CPC分类号： C07K16/289 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

摘要： A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

摘要翻译： 包含至少一个抗原结合位点的分子，其包含高变区CDR1，CDR2和CDR3，所述CDR1具有氨基酸序列Asn-Tyr-Ile-Ile-His（NYIIH），所述CDR2具有氨基酸序列Tyr -Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly（YFNPYNHGTKYNEKFKG）和具有氨基酸序列Ser-Gly-Pro-Tyr -Ala-Trp-Phe-Asp-Thr（SGPYAWFDT）; 例如 进一步包含具有氨基酸序列Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln（RASQNIGTSIQ）的高变区CDR1'，CDR2'和CDR3'，CDR1'，CDR2' 具有氨基酸序列Ser-Ser-Ser-Glu-Ser-Ile-Ser（SSSESIS）和具有氨基酸序列Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr（QQSNTWPFT）的CDR3' 例如 可用作药物的嵌合或人源化抗体。

公开(公告)号：US20050069538A1

公开(公告)日：2005-03-31

申请号：US10666332

申请日：2003-09-18

申请人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

发明人： Gregorio Aversa ,  Frank Kolbinger ,  Jose Carballido Herrera ,  Andras Aszodi ,  Jose Saldanha ,  Bruce Hall

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/44

CPC分类号： C07K16/289 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

摘要： A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

摘要翻译： 包含至少一个抗原结合位点的分子，其包含高变区CDR1，CDR2和CDR3，所述CDR1具有氨基酸序列Asn-Tyr-Ile-Ile-His（NYIIH），所述CDR2具有氨基酸序列Tyr -Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly（YFNPYNHGTKYNEKFKG）和具有氨基酸序列Ser-Gly-Pro-Tyr -Ala-Trp-Phe-Asp-Thr（SGPYAWFDT）; 例如 进一步包含具有氨基酸序列Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin（RASQNIGTSIQ）的高变区CDR1'，CDR2'和CDR3'，CDR1'，CDR2' 具有氨基酸序列Ser-Ser-Ser-Glu-Ser-Ile-Ser（SSSESIS）和具有氨基酸序列Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr（QQSNTWPFT）的CDR3' 例如 可用作药物的嵌合或人源化抗体。